Drugs / Human Rabies Immunoglobulins (HRIG)
Human Rabies Immunoglobulins (HRIG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03145766 Background | Apr 2017 → Jan 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Rabies Immunoglobulins (HRIG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145766 ↗ |
| Modality | Protein / enzyme biologic | “All participants received human rabies immunoglobulin intramuscularly on D0.” PMID 37921410 ↗ Nov 2023 |
| Route | Intramuscular | “All participants received human rabies immunoglobulin intramuscularly on D0.” PMID 37921410 ↗ Nov 2023 |